ArriVent BioPharma, Inc. (AVBP): Insider Trading, Congress Trades & Research | Tormere

AVBP

$13.49+3.61%visit website

ArriVent BioPharma, Inc.

Market Cap

$665M

Live price × SEC shares (Aug 10, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.66

33mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

1.8

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	32,167	32,175	37,617	42,339	144,298
Total operating expenses	38,316	38,823	46,111	52,691	175,941
Operating income	(38,316)	(38,823)	(46,111)	(52,691)	(175,941)
Net income	(34,978)	(35,544)	(43,320)	(49,893)	(163,735)
EPS (basic) ($)	(0.83)		(0.96)	(1.05)	(3.55)
EPS (diluted) ($)	(0.83)		(0.96)	(1.05)	(3.55)
Weighted avg. shares (basic)	41,913		45,068	47,607
Weighted avg. shares (diluted)	41,913		45,068	47,607

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 12, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 10 more quarters, back to Mar 2023, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

ORBIMED ADVISORS LLC · 2026-10-08

No Form 4 transactions on record.

Recent News

ArriVent BioPharma, Inc. (AVBP) stock price, news, quote and history

Yahoo Finance UK · 2026-11-03

Aarvik Therapeutics Announces Milestone Achievement, Partnership Update, and Presentations on MUTTA™ and AQUALINK™ Platforms at the 17th Annual WADC Conference

Yahoo · 2026-11-02

A cancer drug has reached its first patient in a U.S. trial. It’s the first from Aarvik’s platform to enter testing.

Stock Titan · 2026-11-02

Guggenheim Maintains Buy on ArriVent BioPharma, Raises Price Target to $30

Benzinga · 2026-10-27

ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

Yahoo · 2026-10-27

ArriVent BioPharma (AVBP) Advances ARR 217 Into Phase 1b, Is The Selloff Overdone?

Yahoo · 2026-10-27

12 Health Care Stocks Moving In Monday's Intraday Session

Benzinga · 2026-10-26

Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Benzinga · 2026-10-26

ArriVent Announced Sunday, Initial Phase 1 Data For CDH17-Targeted ADC ARR-217 In Gastrointestinal Cancers At ESMO, Demonstrating 44.8% Objective Response Rate At 6mg/kg Dose In Late-Line Colorectal Cancer Patients

Benzinga · 2026-10-25

ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

Yahoo · 2026-10-25

Why ArriVent BioPharma Stock Is In Focus After Trial Failure And Legal Probe

Yahoo · 2026-10-24

ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026

Yahoo · 2026-10-23

ArriVent BioPharma To Present Initial Safety, Efficacy Results Of Its Phase 1 Trial Of CDH17-Targeted ADC ARR-217 In Participants With Gastrointestinal Cancers At ESMO Congress 2026

Benzinga · 2026-10-23

B. Riley Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29

Benzinga · 2026-10-20

ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer

Yahoo Finance · 2026-10-19

Informational purposes only, not investment advice.